XTL Biopharmaceuticals Ltd. General and Administrative Expenses 2011-2026 | XTLB

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses XTL Biopharmaceuticals Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	1 M	910 K	807 K	755 K	1.19 M	1.26 M	1.41 M	1.72 M	1.98 M	2.77 M	1.08 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.77 M	755 K	1.35 M

Quarterly General and Administrative Expenses XTL Biopharmaceuticals Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	297 K	-	-	-	206 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
297 K	206 K	252 K

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Apellis Pharmaceuticals APLS	550 M	$ 20.36	-1.64 %	$ 2.57 B	USA
Aptorum Group Limited APM	5.41 M	$ 0.81	-3.83 %	$ 4.42 M	China
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Axsome Therapeutics AXSM	63.3 M	$ 164.62	-1.06 %	$ 8.19 B	USA
AbCellera Biologics ABCL	83.2 M	$ 3.74	-2.23 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	99.3 M	$ 8.57	-1.95 %	$ 1.39 B	Britain
Certara CERT	85.4 M	$ 7.27	3.05 %	$ 1.17 B	USA
Catalyst Pharmaceuticals CPRX	63.1 M	$ 23.94	0.23 %	$ 2.93 B	USA
Corvus Pharmaceuticals CRVS	6.88 M	$ 18.1	1.17 %	$ 869 M	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Eton Pharmaceuticals ETON	18.9 M	$ 17.89	-1.43 %	$ 459 M	USA
Exelixis EXEL	519 M	$ 40.99	-0.1 %	$ 11.1 B	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	12.8 M	$ 26.27	-2.2 %	$ 703 M	USA
Galapagos NV GLPG	141 M	$ 33.2	-2.61 %	$ 2.69 B	Belgium
Greenwich LifeSciences GLSI	3.06 M	$ 27.98	2.15 %	$ 364 M	USA
Galecto GLTO	12.7 M	$ 29.63	-1.39 %	$ 787 M	Danmark
Genmab A/S GMAB	661 M	$ 27.76	-6.37 %	$ 17.6 B	Danmark
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	55.1 M	$ 1.0	-1.47 %	$ 73.4 M	USA
Halozyme Therapeutics HALO	207 M	$ 69.4	-0.64 %	$ 8.32 B	USA
Hoth Therapeutics HOTH	4.97 M	$ 1.01	-0.98 %	$ 6.44 M	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Harmony Biosciences Holdings HRMY	153 M	$ 28.63	-0.95 %	$ 1.65 B	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
ImmuCell Corporation ICCC	2.22 M	$ 6.3	-3.67 %	$ 51.5 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Immuron Limited IMRN	3.52 M	$ 0.75	-0.69 %	$ 6.46 M	Australia
Immatics N.V. IMTX	33.8 M	$ 9.95	-0.4 %	$ 626 M	Germany
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Immunic IMUX	21.2 M	$ 1.12	5.19 %	$ 174 M	USA
Agenus AGEN	78.7 M	$ 3.24	-3.14 %	$ 1.16 M	USA
Immunovant IMVT	77.2 M	$ 27.24	-1.84 %	$ 4.13 B	USA
Inhibrx INBX	29.4 M	$ 76.35	-1.47 %	$ 3.6 B	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
InMed Pharmaceuticals INM	369 K	$ 0.78	-4.88 %	$ 1.91 M	Canada
INmune Bio INMB	9.62 M	$ 1.39	4.66 %	$ 25 M	USA
Insmed Incorporated INSM	701 M	$ 147.23	0.62 %	$ 29.3 B	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA